Clinical Trial Update: A Study Evaluating Platinum-Pemetrexed-Atezolizumab (+/-Bevacizumab) for Patients With Stage IIIB/IV Non-squamous Non-small Cell Lung Cancer With EGFR Mutations, ALK Rearrangement or ROS1 Fusion Progressing After Targeted Therapies [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating platinum-pemetrexed-atezolizumab with or without bevacizumab for stage IIIB/IV non-squamous non-small cell lung cancer that progresse…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer
• Non-small Cell Lung Cancer with Alk Rearrangement
• Non-small Cell Lung Cancer with Egfr Mutation
• Non-small Cell Lung Cancer with Ros1 Fusion

Drugs mentioned

• Atezolizumab (atezolizumab)
• Bevacizumab (bevacizumab)
• CARBOPLATIN (Carboplatin)
• CISPLATIN (cisplatin)
• Pemetrexed (pemetrexed)

Snippet

Sponsor: Centre Francois Baclesse | Conditions: NSCLC Stage IIIB, NSCLC Stage IV | Phase 2 | Status: COMPLETED